DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) ...( REYKJAVIK Iceland June 30 /- deCO...),Health

REYKJAVIK, Iceland, June 30 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced positive topline results from its latest clinical pharmacology study of DG041, the company's first-in-class antagonist of the EP3 receptor for prostaglandin E2, developed as a next-generation oral anti-platelet therapy for preventing arterial thrombosis without increasing bleeding risk. The prospective, randomized, blinded, crossover study compared the effects on platelet activation and bleeding time of DG041 alone and in combination with the mainstays of current antiplatelet treatment, Plavix(TM) (clopidogrel) and aspirin. The results confirm previous clinical findings that DG041 inhibits platelet aggregation without increasing bleeding time as monotherapy, and further demonstrated that in combination with clopidogrel alone, as well as with clopidogrel and aspirin, DG041 provided additional antiplatelet effect without prolonging bleeding time.

deCODE's product development team will discuss the results of this study in detail at the company's annual R&D event to be webcast live today beginning at 1pm Eastern Time through the investor's page of the company's website, http://www.decode.com.

"These findings underscore the potential of DG041 as a next-generation oral anti-platelet: a compound that can reduce the risk of thrombi formation without increasing overall bleeding risk. While the current standard of care, clopidogrel and aspirin, has been shown to be effective in decreasing the risk of blood clots leading to heart attack and stroke, they do so in an untargeted manner and thus raise the likelihood of unwanted bleeding. By targeting EP3, which we identified through our huma
'/>"/>